Wockhardt LimitedQ1 FY27 Results & Financial Update
Wockhardt Limited: Q1 FY27 consolidated results and company financials – revenue ₹929.00 Cr, PAT ₹107.00 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceReported figures and period changes.Changes compare like-for-like reported periods where available.
Find an answer
Ask this result
Chart · Market context
Wockhardt price & chart
Market price₹2,083.90
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Wockhardt Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Wockhardt sustained its positive operating momentum during the first quarter of fiscal 2027, reporting consolidated revenue from operations of Rs. 929 crore, representing a 26 percent expansion compared to Rs. 738 crore registered in the corresponding quarter of the previous year.
The robust financial performance was underpinned by strong traction in the biotechnology segment—specifically insulin portfolios across emerging markets—alongside steady execution in key branded formulations and international territories.
EBITDA for the quarter stood at Rs. 188 crore, reflecting an 86 percent surge over the Rs. 101 crore reported in Q1 FY26, with EBITDA margins expanding to 20.2 percent from 13.7 percent previously.
Research and development investments remained a core strategic pillar, with R&D expenditure recorded at Rs. 34 crore, maintaining focused clinical advancement on the company's proprietary anti-infective pipeline.
Management highlighted significant regulatory milestones achieved during the period, notably US FDA and Indian CDSCO approvals for novel antibiotic Zaynich, marking a foundational leap for home-grown drug commercialisation.
01 · Business model
What does Wockhardt do?
Wockhardt Limited is a research-based global pharmaceutical and biotechnology major engaged in the manufacturing and marketing of formulations, biologicals, and novel anti-infectives.
The company operates robust, vertically integrated research and manufacturing facilities spanning India, the United Kingdom, and Ireland, serving major international markets across Europe, Emerging Markets, and India.
Wockhardt derives roughly 78% of its global revenues from international businesses, anchored by specialized strengths in biotech operations, insulin ranges, and novel drug discovery programs targeting difficult-to-manage superbugs.
The economic and operating model centers on shifting from generic portfolios toward high-value proprietary biosimilars and first-in-class novel chemical entities (NCEs) protected by global intellectual property.
02 · Historical context
What shaped the business before this quarter
Over the preceding two decades, Wockhardt directed substantial capital and research efforts into addressing antimicrobial resistance, establishing a specialized New Drug Discovery Programme focusing on untreatable superbugs.
Earlier clinical milestones culminated in successful Phase 3 trials for multiple novel antibiotics, laying the groundwork for regulatory filings and subsequent global approvals.
03 · Financial snapshot
Current quarter vs the two useful baselines
| Metric | Q1 FY27 | Year-ago | Previous quarter |
|---|---|---|---|
| Revenue from operations | ₹929.00 Cr | ₹738.00 Cr | ₹965.00 Cr |
| Total income | ₹960.00 Cr | ₹758.00 Cr | ₹1,010.00 Cr |
| Profit before tax | ₹116.00 Cr | ₹-109.00 Cr | ₹189.00 Cr |
| Profit after tax | ₹107.00 Cr | ₹-108.00 Cr | ₹164.00 Cr |
| EPS | ₹6.55 | ₹-5.53 | ₹10.23 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Overall biotech operations scaled to Rs. 236 crore, posting a 112 percent year-on-year jump, led by a 146 percent surge in emerging market biotech driven by insulin products and new deal acquisitions in Brazil, Thailand, Egypt, Algeria, and LATAM.
Domestic branded operations reached Rs. 156 crore, growing 21 percent year-on-year, supported by strong performance in diabetic therapy, NCE Emrok, and the introduction of the regenerative derma segment.
The UK business stood at GBP 27 million (steady at Rs. 343 crore), emerging markets contributed Rs. 263 crore up 64 percent, and the Irish region recorded Rs. 64 crore, marking a 28 percent year-on-year increase.
What drove margins
Higher capacity utilization across biotech and branded manufacturing lines helped expand EBITDA margins to 20.2 percent in Q1 FY27 from 13.7 percent in Q1 FY26.
A greater proportion of high-value biosimilars and novel therapeutics contributed to improved gross margins and overall profitability compared to the previous year's loss-making base.
R&D expenses were maintained at Rs. 34 crore (3.6 percent of sales), ensuring disciplined allocation toward ongoing clinical and regulatory submissions without disproportionately straining operating earnings.
05 · Demand, customers & order book
Where demand is coming from
Emrok and Emrok O brands continued expanding their footprint, treating approximately 150,000 patients and recording 29 percent year-on-year growth in Q1 FY27.
06 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
Total biotech revenue reached Rs. 236 crore, representing 112 percent growth over Q1 FY26, anchored by end-to-end integrated infrastructure and expanding global insulin analog pipelines.
Domestic formulations grew robustly, backed by diabetic therapies and specialized hospital products, while international business recorded 12 filings, 9 approvals, and 5 launches.
Geography and market mix
Emerging markets achieved Rs. 263 crore in revenue, up 64 percent year-on-year, propelled by insulin demand and significant traction from newly acquired distribution deals in Latin America.
UK operations contributed GBP 27 million, while Irish operations delivered Rs. 64 crore, reflecting a 28 percent year-on-year growth trajectory in European territories.
07 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Wockhardt leveraged its robust, end-to-end integrated biotech manufacturing facilities in India, the UK, and Ireland to support rising global demand for insulin and biologicals.
08 · Strategy & new businesses
How the company is trying to change its growth mix
The company positioned its upcoming launch of insulin analogs over the next few years as a major strategic growth driver to strengthen its leadership in global diabetes care.
Wockhardt advanced its portfolio of five novel antibiotics that have completed Phase 3 clinical trials successfully, spearheaded by regulatory approvals for Zaynich.
09 · Reported developments
What changed operationally
Zaynich received US FDA approval on May 30, 2026, and CDSCO approval on May 28, 2026, for complicated urinary tract infections, marking the first-ever India-discovered and developed drug to gain US FDA approval.
The DCGI removed the 'supply condition' for Miqnaf (Nafithromycin), facilitating direct marketing access to a wider patient population in India for community-acquired bacterial pneumonia.
The European Medicines Agency (EMA) communicated that the Marketing Authorization Application dossier for Zaynich is adequate for review across multiple severe infection indications.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Intellectual Property Portfolio
Wockhardt filed 1 patent during Q1 FY27, taking its cumulative patent filings to 3,291 with 859 active patents held globally.
Reported update
Global Research Recognition
Wockhardt remains the only company globally with US FDA Qualified Infectious Disease Product (QIDP) status for six anti-bacterial discovery programs, comprising three Gram-negative and three Gram-positive assets.
11 · Previous-quarter changes
What changed since the previous quarter
Consolidated revenue moderated slightly from Rs. 965 crore in Q4 FY26 to Rs. 929 crore in Q1 FY27, while PAT adjusted from Rs. 164 crore to Rs. 107 crore.
12 · Key Q&A
The quarter, answered directly
What does Wockhardt do?
Wockhardt Limited is a research-based global pharmaceutical and biotechnology major engaged in the manufacturing and marketing of formulations, biologicals, and novel anti-infectives.
What is the clearest takeaway from Q1 FY27?
Wockhardt sustained its positive operating momentum during the first quarter of fiscal 2027, reporting consolidated revenue from operations of Rs. 929 crore, representing a 26 percent expansion compared to Rs. 738 crore registered in the corresponding quarter of the previous year.
What drove revenue or demand?
Overall biotech operations scaled to Rs. 236 crore, posting a 112 percent year-on-year jump, led by a 146 percent surge in emerging market biotech driven by insulin products and new deal acquisitions in Brazil, Thailand, Egypt, Algeria, and LATAM.
What mattered most for margins or profitability?
Higher capacity utilization across biotech and branded manufacturing lines helped expand EBITDA margins to 20.2 percent in Q1 FY27 from 13.7 percent in Q1 FY26.
What changed operationally beyond the headline numbers?
Wockhardt leveraged its robust, end-to-end integrated biotech manufacturing facilities in India, the UK, and Ireland to support rising global demand for insulin and biologicals.
What should the next disclosure help confirm?
Monitor the upcoming commercial launch and market uptake of Zaynich following its US FDA and Indian regulatory approvals.
13 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
14 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Zaynich Commercial Rollout: Monitor the upcoming commercial launch and market uptake of Zaynich following its US FDA and Indian regulatory approvals.
- 02
Foviscu Regulatory Milestones: Track the planned New Drug Application filing for Foviscu (WCK 4282) during Q3 FY27 following successful Phase 3 trials.
- 03
EMA Review Progress: Track the progress of the European Medicines Agency Marketing Authorization Application review for Wockhardt's novel antibiotic portfolio.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.